Clues on Clovis

A Bloomberg story suggesting Clovis Oncology Inc. (NASDAQ:CLVS) looked for - but did not find a buyer - last month has weighed on the company's shares. But a further decline last week likely had more to do with data for a competitor's cancer compound.

Clovis shares have been on a tear this year, fueled in part by data reported on June 3 for CO-1686 and rucaparib (CO-338) at the American Society of Clinical Oncology(ASCO) meeting. On that day alone the stock gained $38.01 (104%) to $74.59 (see BioCentury, June 10)...